Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 25, 1999

View Archived Issues

Antifungal agent DuP-991 available for licensing from BTG

Bioniche's IND for bladder cancer treatment granted IND approval

FDA approves phase III protocol for Cypros' Cordox

FDA expands HUD designation for Ortec's Composite Cultured Skin

King completes acquisition from Lilly of U.S. rights to Lorabid

AdProTech and Avecia begin scale-up of APT-070

Medco issued patent covering allosteric adenosine modulators

Texas Biotechnology corrects NDA amendment for Novastan

Japan is country of first launch for migraine prevention agent

Tanabe Seiyaku-Pharmacia & Upjohn collaboration provides new leads in inflammation research

ACS presentation for Parke-Davis's selective NR1a/2B receptor antagonist PD-188669

News from ACS: Abbott and Icos describe antiinflammatory ICAM-1 inhibitor

MRS-1595: a novel adenosine antagonist selective for the A2B receptor

Yoshitomi discloses cytokine production inhibitors for treating and preventing allergic reactions

Retrospective study supports safety of xenotransplantation

More antiviral agents against CMV discovered at Bayer

Anticoagulant factor Xa inhibitors reported by Mochida

Antimycotic agents, triazole derivatives prepared and evaluated by Japanese lab

Tanabe Seiyaku pursues integrin receptor antagonists, with interesting results

InterMune files BLA for Actimmune for treatment of osteopetrosis

Berlex acquires marketing rights to Campath

BioCryst reports initial phase II results from worldwide influenza collaboration

Cardioselective potassium channel blocker advances to phase II trials at HMR

Academic researchers identify MAb as effective treatment for PCP addiction

Allergan receives approvable letter for Restasis

FDA grants priority review to Visudyne NDA

ACS presentation for new factor Xa inhibitor from Rhone-Poulenc Rorer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...